The healthcare world is ablaze with news surrounding retatrutide, a promising peptide currently being investigation for weight-related conditions. Formulated by Zealand Pharma, retatrutide acts as a dual stimulator for both GLP-1 and GIP receptors, influencing appetite and blood sugar metabolism